 | Up a level |
Papaefthymiou, Apostolis; Doulberis, Michael; Karafyllidou, Kyriaki; Chatzimichael, Eleftherios; Deretzi, Georgia; Exadaktylos, Aristomenis K.; Sampsonas, Fotios; Gelasakis, Athanasios; Papamichos, Spyros I.; Kotronis, Georgios; Gialamprinou, Dimitra; Vardaka, Elisabeth; Polyzos, Stergios A.; Kountouras, Jannis (2023). Effect of spironolactone on pharmacological treatment of nonalcoholic fatty liver disease. Minerva endocrinology, 48(3), pp. 346-359. Edizioni Minerva Medica 10.23736/S2724-6507.21.03564-8
Doulberis, Michael; Papaefthymiou, Apostolis; Srivastava, David S.; Exadaktylos, Aristomenis K.; Katsinelos, Panagiotis; Kountouras, Jannis; Polyzos, Stergios A. (2021). Update on the association between non‐alcoholic fatty liver disease and Helicobacter pylori infection. International Journal of Clinical Practice, 75(4), e13737. Wiley 10.1111/ijcp.13737
Doulberis, Michael; Pierre, Noah Thierry; Manzini, Giulia; Papaefthymiou, Apostolis; Kountouras, Jannis; Klukowska-Rötzler, Jolanta; Polyzos, Stergios A.; Srivastava, Simone; Exadaktylos, Aristomenis K.; Knuchel, Jürg; Kuntzen, Thomas; Srivastava, David S. (2021). Helicobacter pylori-Related Metabolic Parameters and Premalignant Gastric Mucosa Histological Lesions in Swiss Bariatric Patients. Microorganisms, 9(7), p. 1361. MDPI 10.3390/microorganisms9071361
Kountouras, Jannis; Doulberis, Michael; Papaefthymiou, Apostolis; Polyzos, Stergios A. (2020). Impact of Helicobacter pylori ‐linked metabolic syndrome on non‐alcoholic fatty liver disease and its connected atrial fibrillation risk. Liver international, 40(8), pp. 2036-2037. Wiley 10.1111/liv.14488
Papaefthymiou, Apostolis; Doulberis, Michael; Polyzos, Stergios A.; Katsinelos, Panagiotis; Liatsos, Christos; Koffas, Apostolos; Kazakos, Evangelos; Deretzi, Georgia; Srivastava, David S.; Kountouras, Jannis (2020). Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease. Alimentary pharmacology & therapeutics, 51(2), pp. 313-314. Wiley-Blackwell 10.1111/apt.15608
